A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

More documents

Recommendations

Info

Flowers ME, Storer BE, Lee SJ, et al. Risk Factors for the Development ofAcute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease(GVHD). Blood. 2009;114 (abstr 345)
Will CBMTG 0801 succeed?In part for sureIn totality - hopefullyWill the decrease in cGVHD have meaning for patientsi.e. less immunosuppression, better quality of life, andless medicalization…. and for the administrators: noextra cost (or maybe even cost savings)?
Page 1 and 2: A Randomized Trial of Thymoglobulin
Page 3 and 4: Appendix AIllustrations of cGVHD -
Page 5: Quality of LifeFraser CJ et al. Imp
Page 12 and 13: A Randomized Trial of Thymoglobulin
Page 14 and 15: FundingTOTAL GRANT:CIHR:$1,245,055
Page 16 and 17: FinkeLancet Oncol 2009;10: 855-64Ba
Page 18 and 19: Time to Onset of Prednisone RxMielk
Page 20 and 21: Secondary End-Points• Time to eng
Page 22 and 23: Treatment Plan - ThymoglobulinThe e
Page 24 and 25: Flu-Bu-ATG (Slavin) vs F-TBI (Seatt
Page 26 and 27: Benefits and Harms• BENEFITS• L
Page 28 and 29: PTLD in Unrelated/Mismatch +ATGStud
Page 30 and 31: Performance of QPCR test for EBVAss
Page 32 and 33: cGVHD Manifestions - NIHFilipovich
Page 34 and 35: cGVHD Case Report Form (CRF)
Page 36 and 37: cGVHD Case Report Form (CRF)
Page 38 and 39: Body Surface Area (Rule of 9)
Page 40 and 41: Will CBMTG 0801 succeed?In part for
Page 44: Thank you

A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?